Dr. Reddy's Laboratories Ltd (RDY): Price and Financial Metrics
GET POWR RATINGS... FREE!
RDY POWR Grades
- Growth is the dimension where RDY ranks best; there it ranks ahead of 95.91% of US stocks.
- RDY's strongest trending metric is Growth; it's been moving up over the last 169 days.
- RDY's current lowest rank is in the Momentum metric (where it is better than 12.3% of US stocks).
RDY Stock Summary
- RDY's current price/earnings ratio is 2,896.9, which is higher than 99.78% of US stocks with positive earnings.
- With a price/sales ratio of 263.56, Dr Reddys Laboratories Ltd has a higher such ratio than 98.74% of stocks in our set.
- As for revenue growth, note that RDY's revenue has grown -98.4% over the past 12 months; that beats the revenue growth of just 0.77% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Dr Reddys Laboratories Ltd, a group of peers worth examining would be MLP, APPF, AGRO, ICCC, and FMX.
- Visit RDY's SEC page to see the company's official filings. To visit the company's web site, go to www.drreddys.com.
RDY Stock Price Chart Interactive Chart >
RDY Price/Volume Stats
| Current price | $55.95 | 52-week high | $75.50 |
| Prev. close | $55.33 | 52-week low | $54.15 |
| Day low | $54.15 | Volume | 192,869 |
| Day high | $56.29 | Avg. volume | 112,102 |
| 50-day MA | $61.81 | Dividend yield | 0.51% |
| 200-day MA | $66.21 | Market Cap | 9.31B |
Dr. Reddy's Laboratories Ltd (RDY) Company Bio
Dr. Reddy's Laboratories operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company was founded in 1984 and is based in Hyderabad, India.
Latest RDY News From Around the Web
Below are the latest news stories about Dr Reddys Laboratories Ltd that investors may wish to consider to help them evaluate RDY as an investment opportunity.
OTC Drugs Market Size [2022-2028] | is Projected to Reach USD 233.6 Billion with 5.8% CAGRPune, India, Jan. 10, 2022 (GLOBE NEWSWIRE) -- The global OTC drugs market size is projected to grow from USD 157.0 billion in 2021 to USD 233.6 billion in 2028. The rising number of private label products is set to affect growth positively. In the U.S., shares of these products reached 31.0% in 2018 from 26.0% in 2009. Also, numerous companies are collaborating with e-commerce platforms to launch their products on their platforms. Amazon.com, Inc., for instance, introduced Perrigo''s over-the-counter healthcare products in February 2018. Fortune Business Insights mentioned this in a published report, titled, " OTC Drugs Market, 2021-2028 ." The report further states that the market stood at USD 148.0 billion in 2020. It is set to showcase a CAGR of 5.8% in the forecast period during 20... |
Aurobindo Pharma introduces Covid-19 drug Molnupiravir in IndiaAurobindo Pharma launches Covid-19 drug Molnupiravir in India.Earlier this week, the pharmaceutical major Dr Reddy''s Laboratories Ltd said it will soon launch the generic version of Merck''s antiviral Covid-19 pill, Molnupiravir |
UPDATE 1-Dr Reddy's to launch generic COVID-19 Merck drug at about 50 cents a pillIndian drugmaker Dr Reddy's Laboratories Ltd will launch its generic version of Merck's antiviral COVID-19 pill, molnupiravir, and price it at 35 rupees ($0.4693) per capsule, a company spokesperson said on Tuesday. The overall cost for a patient treated with a 5-day course of 40 capsules of the generic drug, to be sold under brand name 'Molflu', will come up to 1,400 rupees ($18.77). In comparison, the treatment with Merck's pill in the United States costs $700. |
Dr. Reddy’s and Prestige BioPharma announce partnership to commercialize biosimilar for cancer treatment in select countries in Latin America and Southeast AsiaHYDERABAD, India, December 15, 2021--Prestige BioPharma and Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as "Dr. Reddy’s") today announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialization of Prestige BioPharma’s proposed biosimilar for the treatment of cancer in select countries in Latin America and Southeast Asia. |
Prestige BioPharma and Dr. Reddy’s Announce Partnership to Commercialize Trastuzumab Biosimilar in Select Countries in Latin America and Southeast AsiaSINGAPORE & HYDERABAD, India, December 14, 2021--Prestige BioPharma and Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as "Dr. Reddy’s") today announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialization of Prestige BioPharma’s proposed trastuzumab biosimilar in select countries in Latin America and Southeast Asia. |
RDY Price Returns
| 1-mo | -13.20% |
| 3-mo | -8.94% |
| 6-mo | -10.55% |
| 1-year | -14.60% |
| 3-year | 53.91% |
| 5-year | 30.40% |
| YTD | -14.46% |
| 2021 | -7.49% |
| 2020 | 76.61% |
| 2019 | 8.38% |
| 2018 | 1.18% |
| 2017 | -16.47% |
RDY Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching RDY
Want to do more research on Dr Reddys Laboratories Ltd's stock and its price? Try the links below:Dr Reddys Laboratories Ltd (RDY) Stock Price | Nasdaq
Dr Reddys Laboratories Ltd (RDY) Stock Quote, History and News - Yahoo Finance
Dr Reddys Laboratories Ltd (RDY) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...